Expressing the sense of the House of Representatives that biotechnology firms meeting small business standards are critical to the United States, its people and its economy because they create new medicines, services, and jobs and meet unmet needs related to populations and patients with infectious and chronic diseases, including those of medically underserved populations.
About This Bill
Committee
Latest Action · March 12, 2010
Referred to the House Committee on Energy and Commerce.